Fate Therapeutics, Inc.
FATE
$0.9205
-$0.0458-4.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.86M | 3.07M | 6.77M | 1.93M | 1.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.86M | 3.07M | 6.77M | 1.93M | 1.68M |
| Cost of Revenue | 17.14M | 34.65M | 34.60M | 32.14M | 16.41M |
| Gross Profit | -15.28M | -31.58M | -27.83M | -30.21M | -14.73M |
| SG&A Expenses | 31.73M | 20.80M | 17.25M | 20.86M | 33.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.87M | 55.45M | 51.86M | 52.99M | 49.75M |
| Operating Income | -47.01M | -52.38M | -45.08M | -51.07M | -48.08M |
| Income Before Tax | -52.15M | -47.68M | -38.43M | -48.00M | -44.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.15M | -47.68M | -38.43M | -48.00M | -44.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.15M | -47.68M | -38.43M | -48.00M | -44.12M |
| EBIT | -47.01M | -52.38M | -45.08M | -51.07M | -48.08M |
| EBITDA | -42.20M | -47.77M | -40.36M | -46.25M | -43.19M |
| EPS Basic | -0.44 | -0.40 | -0.33 | -0.47 | -0.45 |
| Normalized Basic EPS | -0.20 | -0.25 | -0.20 | -0.30 | -0.31 |
| EPS Diluted | -0.44 | -0.40 | -0.33 | -0.47 | -0.45 |
| Normalized Diluted EPS | -0.20 | -0.25 | -0.20 | -0.30 | -0.31 |
| Average Basic Shares Outstanding | 117.79M | 117.77M | 117.47M | 101.10M | 98.61M |
| Average Diluted Shares Outstanding | 117.79M | 117.77M | 117.47M | 101.10M | 98.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
